1. Effect of nanoencapsulation using poly (lactide-co-glycolide) (PLGA) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy
- Author
-
Xiao-Pei Zhang, Jian-Guo Sun, Kun Shan, Hui-Min Ge, Biao Yan, Qin Jiang, Chen Zhao, Mu-Di Yao, Jin Yao, and Bai-Hui Liu
- Subjects
Male ,Vascular Endothelial Growth Factor A ,genetic structures ,Bevacizumab ,Biological Availability ,Angiogenesis Inhibitors ,macromolecular substances ,02 engineering and technology ,Retinal Neovascularization ,Pharmacology ,Aqueous Humor ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,Drug Delivery Systems ,0302 clinical medicine ,Polylactic Acid-Polyglycolic Acid Copolymer ,In vivo ,Human Umbilical Vein Endothelial Cells ,medicine ,Animals ,Humans ,Corneal Neovascularization ,Particle Size ,Tube formation ,Drug Carriers ,technology, industry, and agriculture ,General Medicine ,021001 nanoscience & nanotechnology ,medicine.disease ,eye diseases ,Mice, Inbred C57BL ,Vitreous Body ,Endothelial stem cell ,Vascular endothelial growth factor ,PLGA ,chemistry ,Corneal neovascularization ,Drug delivery ,030221 ophthalmology & optometry ,Nanoparticles ,sense organs ,0210 nano-technology ,medicine.drug - Abstract
Antibody-based therapy is an effective strategy for treating ocular angiogenesis. However, short-acting efficacy and poor treatment compliance usually occurs in clinical practices. Thus, it is required to develop a drug delivery system to improve the bioavailability and decrease the toxicity of anti-angiogenic antibody. Bevacizumab is a recombinant humanized monoclonal antibody against vascular endothelial growth factor (VEGF). In this study, bevacizumab was encapsulated into poly (lactide-co-glycolide) (PLGA) nanoparticles. PLGA encapsulation could prolong the residency of bevacizumab in the vitreous and aqueous humor and produce long-lasting drug concentrations. Bevacizumab-encapsulated PLGA had no significant cytotoxicity and tissue toxicity effect in vitro and in vivo. In vitro studies showed that bevacizumab-encapsulated PLGA was more effective than bevacizumab in inhibiting VEGF-mediated endothelial cell proliferation, migration and tube formation. In vivo studies showed that bevacizumab-encapsulated PLGA enhanced the anti-angiogenic efficiency of bevacizumab for treating corneal neovascularization and retinal neovascularization. Thus, bevacizumab-encapsulated PLGA could increase the bioavailability and decrease the toxicity of bevacizumab during ocular angiogenesis therapy.
- Published
- 2018
- Full Text
- View/download PDF